^
    Back
    Association details:
    Biomarker:PDZK1IP1 overexpression
    Cancer:Pancreatic Cancer
    Drug:Ninlaro (ixazomib) (Proteasome inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    ESMO-GI 2023
    Title:

    Prognostic and predictive relevance of MAP17 in pancreatic cancer

    Published date:
    06/27/2023
    Excerpt:
    ...MAP17 overexpression predicted, in vitro, efficacy to gemcitabine, cisplatin, 5-fluorouracil and osimertinib, as well as resistance to docetaxel, bortezomib and ixazomib. However, in vivo, MAP17-expressing tumors were clearly resistant to all treatments...MAP17 could serve as a prognostic and predictive biomarker in PC...